Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jin Medical InternationalZJYL 63 ROC (Joel Greenblatt) % is 15.34% as of Sep. 2025, which is 50% below its 10-year median of 30.58. GuruFocus rates ZJYL with a GF Scoreâ„¢ of 63/100 and a GF Valueâ„¢ of $14.59 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 837 Medical Devices & Instruments companies, Jin Medical International ranks better than 50.42% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Jin Medical International's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2025 was 15.34%.
The historical rank and industry rank for Jin Medical International's ROC (Joel Greenblatt) % or its related term are showing as below:
ZJYL'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 4.26 Med: 30.58 Max: 39.8
Current: 4.62
During the past 6 years, Jin Medical International's highest ROC (Joel Greenblatt) % was 39.80%. The lowest was 4.26%. And the median was 30.58%.
ZJYL's ROC (Joel Greenblatt) % is ranked better than 50.42% of 837
companies
in the Medical Devices & Instruments industry
Industry Median: 4.35
vs ZJYL: 4.62
Jin Medical International's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -20.20% per year.
Jin Medical International (NAS:ZJYL) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Jin Medical International ROC (Joel Greenblatt) % Related Terms
Jin Medical International ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Jin Medical International's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jin Medical International ROC (Joel Greenblatt) % Chart
ZJYL vs RGNT, BNGO, RVP: ROC (Joel Greenblatt) % Comparison
For the Medical Instruments & Supplies subindustry, Jin Medical International's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jin Medical International ROC (Joel Greenblatt) % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Jin Medical International's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Jin Medical International's ROC (Joel Greenblatt) % falls into.
Jin Medical International ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is two times the semi-annual (Sep. 2025) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 15.34% mean?
Jin Medical International (ZJYL) has a ROC (Joel Greenblatt) % of 15.34% as of Sep. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Jin Medical International and its competitors. This is 50% below median its historical median of 30.58. Over the past decade, Jin Medical International's ROC (Joel Greenblatt) % has ranged from 4.26 to 39.80. According to the industry distribution chart, Jin Medical International ranks #415 out of 837 companies in the Medical Devices & Instruments industry, placing it in the top 49.6%.
Is Jin Medical International's ROC (Joel Greenblatt) % too high?
Jin Medical International's current ROC (Joel Greenblatt) % of 15.34% is 50% below median its 10-year median of 30.58. Over the past 10 years, this metric has ranged from a low of 4.26 to a high of 39.80. The Medical Devices & Instruments industry median ROC (Joel Greenblatt) % is 4.35. Jin Medical International's value of 15.34% is 252.6% above this industry median. Based on the distribution chart, Jin Medical International ranks #415 out of 837 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Jin Medical International has a GF Scoreâ„¢ of 63/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Jin Medical International's ROC (Joel Greenblatt) % compare to RGNT and BNGO?
According to the Medical Devices & Instruments industry distribution chart, Jin Medical International ranks #415 out of 837 companies for ROC (Joel Greenblatt) %. This puts Jin Medical International in the upper half of its industry. The industry median ROC (Joel Greenblatt) % is 4.35. Jin Medical International's value of 15.34% is 252.6% above this benchmark. Historically, Jin Medical International's own ROC (Joel Greenblatt) % has ranged from 4.26 to 39.80 over the past decade. While the company's 10-year median is 30.58 vs. the industry median of 4.35, Jin Medical International has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median ROC (Joel Greenblatt) % among Medical Devices & Instruments companies is 4.35, based on 837 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jin Medical International's current ROC (Joel Greenblatt) % of 15.34% is 252.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Jin Medical International and its competitors. For the Medical Devices & Instruments industry, the median ROC (Joel Greenblatt) % is 4.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jin Medical International's current ROC (Joel Greenblatt) % is 15.34%, which is 50% below median its own 10-year median of 30.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jin Medical International stock overvalued right now?
Based on GuruFocus' analysis, Jin Medical International (ZJYL) is currently considered Significantly Undervalued. The stock's GF Value™ is $14.59, compared to a current price of $2.00 — trading 86.3% below its estimated fair value. The current ROC (Joel Greenblatt) % is 15.34%, which is 50% below median its 10-year median of 30.58 and 252.6% above the Medical Devices & Instruments industry median of 4.35. Jin Medical International's overall GF Score™ is 63/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Jin Medical International (ZJYL), the current ROC (Joel Greenblatt) % is 15.34% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jin Medical International (ZJYL) Overvalued in 2026?
Based on GuruFocus' analysis, Jin Medical International stock appears to be undervalued.
The current stock price of $2.00 is trading 86.3% below its estimated GF Value™ of $14.59.
GuruFocus considers Jin Medical International to be Significantly Undervalued.
Key valuation signals for ZJYL:
ROC (Joel Greenblatt) %: 15.34% (50% below median its 10-year median of 30.58)
GF Value™: $14.59 vs. price of $2.00 (86.3% below fair value)
Industry Position: 252.6% above the Medical Devices & Instruments median (#415 of 837)
No single metric tells the full story. See the ZJYL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jin Medical International Ltd, along with its subsidiaries, mainly offers rehabilitation equipment. It is engaged in the design, development, manufacturing, and sales of wheelchairs and other assistive living aid products for use by people with disabilities or impaired mobility. The group's product offering includes wheelchairs and wheelchair components, oxygen concentrators, bathing machines, respiratory and walking aids, oxygen chambers, beauty instruments, and nano products, among others. Wheelchairs are currently its key revenue-generating product. The products are sold to dealers in Japan and China, and to some extent to dealers located in the United States, Canada, Australia, Korea, Israel, Singapore, and other regions. Geographically, the group generates maximum revenue from Japan.
63GF Score
Get the complete analysis for ZJYL
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZJYL has been successfully added to your 
